Trèves R, Morvan C, Bitaudeau P, Clément S, Liozon E, Arnaud M, Archambeaud-Mouveroux F, Desproges-Gotteron R
Service de Rhumatologie, CHRU de Limoges.
Rev Rhum Mal Osteoartic. 1988 Jul-Sep;55(9):641-6.
The SASP was studied in 46 patients with rheumatoid arthritis. The efficacy criteria which were selected (decrease of the sed rate by more than 50 p. cent during the first hour, morning stiffness under 20 minutes, Ritchie's index inferior to 10 and decreased cortisone and NSAID doses), explain that 25 p. cent of the patients are considered as satisfied after 12 months of trial. The patients selected, present severe forms of the disease or forms resistant to other treatments. The improvement appears significant after the first month. Half of the patients left the trial either because of ineffectiveness, or evolutive relapse (21.73 p. cent) or because of side-effects (28.26 p. cent). The most frequently observed disorders and intolerances are of digestive nature. No serious accident is to be deplored. Such results are in accordance with the data from the literature. The SASP must therefore be considered as the fundamental treatment of rheumatoid arthritis. The new galenic forms, dissolving in the gastro-intestinal tract, have enabled to markedly improve the digestive tolerance.
对46例类风湿性关节炎患者进行了柳氮磺胺吡啶（SASP）研究。所选疗效标准（第1小时内血沉下降超过50%、晨僵时间少于20分钟、里奇指数低于10以及可的松和非甾体抗炎药剂量减少）表明，经过12个月的试验，25%的患者被认为疗效满意。所选患者均为病情严重或对其他治疗耐药的类型。第一个月后改善情况显著。一半的患者因无效、病情进展复发（21.73%）或副作用（28.26%）而退出试验。最常观察到的不适和不耐受情况为消化系统问题。未发生严重不良事件。这些结果与文献数据一致。因此，SASP必须被视为类风湿性关节炎的基础治疗药物。新型胃肠道溶解剂型已显著提高了消化耐受性。
